Exclusive: Metabolomics Pioneer BioTree BioTech Completes Nearly RMB 100 Million in Series B Funding, Bolstering Multi-Omics + AI4S R&D and Global Expansion

On October 10, 2026, Shanghai Biotree Biotech Co., Ltd. (hereinafter referred to as “Biotree”), a leading Chinese metabolomics enterprise, announced the completion of its Series B financing round, raising nearly RMB 100 million. The round was exclusively led by CCMC, with existing shareholder Qiming Venture Partners also participating.

The proceeds from this financing are planned to be used for R&D in multi-omics and AI for Science, new product development in single-cell metabolomics, spatial metabolomics, single-cell proteomics, and spatial proteomics, the construction of a multi-omics and AI mass spectrometry production capacity center in Zhejiang, and the establishment of an overseas headquarters in Singapore as well as laboratories in Europe and the United States. The goal is to advance the practical application of mass spectrometry-based multi-omics and AI technologies in basic scientific research, biopharmaceutical R&D, and clinical medical translation on a global scale.

Deng Junliang, Founder and CEO of Biotree Biotech, stated: Currently, the rapid breakthroughs in frontier artificial intelligence (AI) technologies and their deep integration into life sciences and biomedicine are driving a shift in AI for Science (AI4S) from tool-based assistance to driver-led empowerment. Against the backdrop of vigorous global R&D and innovation in AI for Science, mass spectrometry-based multi-omics data—such as metabolomics and proteomics data, particularly Biotree's MetCell single-cell metabolomics data—serve as natural fuel for models in fields like the AI Virtual Cell (AIVC). These data not only address the issue of insufficient cellular data diversity in AIVC but also enable high-depth, multimodal analysis of metabolic changes and protein expression alterations following drug-induced or genetic perturbations in cells.

Biotree has been deeply engaged in the field of mass spectrometry-based multi-omics for over a decade, consistently focusing on frontier technological innovation and industrial application while continuously iterating its core multi-omics technology systems and industrialization capabilities. AI for Science represents a significant developmental opportunity bestowed by the era upon all multi-omics companies. Biotree will remain true to its original aspiration, forge ahead with determination, and continue to lead the wave of the mass spectrometry-based multi-omics plus AI era.

We extend our heartfelt gratitude to the investors in this round and all shareholders for their high recognition of Biotree Biotechnology's technical strength, business model, and development potential. Moving forward, the company will leverage metabolomics, proteomics, and AI technologies to focus on the broader life sciences sector (encompassing life sciences, biopharmaceuticals, and medical health), with a dedicated emphasis on mass spectrometry technology, adhering to our mission: “Advancing MS Tech, Enhancing Life.”

Project Lead at CCMC stated: The underlying core driving the accelerated implementation of AI in the life sciences sector is the large-scale accumulation and applied utilization of high-quality, multi-dimensional, multi-omics biological data. The recently released "15th Five-Year Plan for the Development of the Pharmaceutical Industry" explicitly calls for promoting the innovative translation of cutting-edge biotechnologies, such as advanced omics. Against this industry backdrop, Biotree has long been deeply engaged in metabolomics, proteomics, and other fields, accumulating a standardized biological database and data analysis methodology with distinct characteristics. The company possesses the foundational capabilities to support scenarios such as AI model training, biomarker discovery, and target identification, positioning it to capitalize on the industry dividends from the convergence of AI and life sciences, thereby achieving rapid business iteration and high-quality growth.

Hu Xubo, Managing Partner of Qiming Venture Partners, stated: Since exclusively leading BioTree's Series A financing round in 2022, Qiming Venture Partners has remained optimistic about and supportive of the company's development. With over a decade of deep expertise in mass spectrometry-based multi-omics, BioTree has established an industry-leading library of metabolite standards and a high-caliber technical platform, solidifying its status as a bona fide benchmark enterprise in the multi-omics sector. Currently, AI for Science is profoundly reshaping research paradigms in life sciences and medicine, with multi-omics data serving as the core cornerstone for constructing virtual cells and models of the living world. By proactively integrating mass spectrometry technology with AI, BioTree has taken the lead in laying out frontier directions such as next-generation metabolomics, single-cell metabolomics, and spatial multi-omics. The company is transforming from a scientific research service provider into a builder of infrastructure and a provider of core data for the AI4S era. We are confident that BioTree will grow into a significant global player in the AI4S field amid this historic opportunity, and we will continue to support the company’s long-term growth.